Basophil Histamine Release Induced by Amoxicilloyl-poly-L-lysine Compared With Amoxicillin in Patients With IgE-Mediated Allergic Reactions to Amoxicillin


*Both authors contributed equally
1Diater Laboratorios, Madrid, Spain
2Department of Dermatology, University Hospital of Odense, Denmark and Charité, Berlin, Germany
3Allergy Service, Ramon y Cajal Hospital, Madrid, Spain
4Department of Pharmacology, University Complutense of Madrid, Spain
5Allergy Unit, Cruz Roja Hospital, Madrid, Spain
6Allergy Unit, IBIMA—Regional University Hospital of Malaga UMA, Málaga, Spain
7Andalusian Center for Nanomedicine and Biotechnology - BIONAND, Málaga, Spain

Abstract

Background: Amoxicillin (AX) is the β-lactam most often involved in IgE-mediated reactions. Diagnosis is based mainly on skin testing, although sensitivity is not optimal. We produced a new AX derivative, amoxicilloyl-poly-L-lysine (APL), and analyzed its recognition of IgE using the passive histamine release test (pHRT).

Methods: The study population comprised patients (n=19) with confirmed AX allergy and specific IgE to AX and controls (n=10) with good tolerance to AX. pHRT was performed using "IgE-stripped" blood from a single donor that was sensitized in vitro by patient sera and incubated with AX or APL. Histamine release was determined and expressed as nanograms of histamine released per milliliter of blood.

Results: The clinical symptoms were anaphylaxis (n=9), urticaria (n=7), erythema (n=2), and non-defined immediate reactions (n=1). The median (IQR) time interval between reaction and study was 90 (60-240) days and between drug intake and development of symptoms 24 (10-60) minutes. The median sIgE level was 3.37 (0.95-5.89) kUA/L. The sensitivity of pHRT to APL was 79% and the specificity 100%, which were higher than data obtained with pHRT to AX (63% sensitivity and 90% specificity). There was a positive correlation between maximal histamine release levels obtained with AX and APL (r=0.63).

Conclusions: In patients with immediate hypersensitivity reactions to AX, APL showed higher sensitivity and specificity than the culprit drug, AX, when tested in vitro by pHRT. This indicates that APL can improve the in vitro diagnostic accuracy of allergic reactions to AX. Further assessment of skin testing is necessary.

Key words: Allergy. Amoxicillin. Amoxicilloyl-poly-L-lysine. Basophil histamine release. Immediate reactions.
Introduction

β-Lactam (BL) antibiotics are still the most frequent cause of IgE-mediated allergic reactions [1-3]. Although all BLs can be responsible, amoxicillin (AX) alone or combined with clavulanic acid and, to lesser extent, cephalosporins, are currently the most frequent culprits [1-3]. AX can induce selective reactions, implying that patients react to this antibiotic while tolerating other BLs such as benzylpenicillin (BP) [4-6], with immunochemical studies indicating that the side chain structure is important for immunological recognition [7-9].

The diagnosis of immediate allergic reactions to AX is based mainly on skin tests or drug provocation tests (DPT), procedures that are time-consuming and not risk-free [10-14]. Skin testing is performed using major and minor determinants of benzylpenicillin and AX, although its sensitivity is less than 70% [11]. The minor determinants of AX, amoxicilloyl and diketopiperazine [15], have been used to increase the sensitivity of skin testing, although neither is more sensitive than AX itself, indicating that new AX structures need to be investigated. Given that benzylpenicilloyl-octa-L-lysine was recently shown to be a stable compound that was useful for skin testing [16], it is tempting to speculate that amoxicilloyl-octa-L-lysine (APL) could be synthetized in a similar way.

In vitro tests, such as ImmunoCAP and the basophil activation test (BAT) are complementary approaches for the diagnosis of allergy to BL [17-20], although the former has low sensitivity [21] and the latter must be performed a few hours after blood extraction by expert personnel [19]. Other cellular tests, such as the passive histamine release test (pHRT), have proven useful for diagnosing clavulanic acid allergy [22]. pHRT is based on the detection of histamine release using “IgE-stripped” donor blood sensitized with patient serum followed by incubation with the antibiotic. It is suitable as a routine diagnostic test, since the plates can be sent to a reference laboratory for histamine detection and data analysis [23].

In this study, we produced a new synthetic product, APL, which is expected to be more stable than the parent drug, AX. Basophil reactivity to both APL and AX was analyzed using pHRT with sera from patients with confirmed immediate allergic reactions to AX. This could be the first step in further evaluation of APL as a useful reagent for diagnosis based on skin testing.

Material and Methods

Patient Selection

The study group included patients diagnosed with immediate allergic reactions to AX in the allergy units of 4 Spanish hospitals during 2013. Diagnosis was based on the European Academy of Allergy and Clinical Immunology (EAACI) general guidelines for the evaluation of immediate reactions to BLs [12].

To be included, patients had to have experienced an allergic reaction within 90 minutes after administration of AX and have serum specific IgE (sIgE) to AX (≥0.35 kU/L). The control group comprised 10 healthy individuals who had previously received AX with no adverse effects, including allergic reactions, and with negative skin test and serum sIgE test results to AX.

The relevant institutional review boards approved the study, and all patients and controls gave their informed consent to participate.

Skin Testing

Skin prick and intradermal tests were carried out as previously described [12], using 0.03 mL of solution prepared daily. The reagents were as follows: benzylpenicilloyl octa-L-lysine (BPOL) 0.04 mg/mL, with a molar concentration of the benzylpenicilloyl (BPO) moiety of 8.64•10–5 M; minor determinant (MD) 0.5 mg/mL, with a molar concentration of the sodium benzylpenilloate of 1.5•10–3 M; and AX 20 mg/mL (Diater Laboratories). In skin prick testing, a wheal larger than 3 mm surrounded by erythema was considered positive. In intradermal tests, the wheal area was marked initially and 20 minutes after testing, and an increase in diameter greater than 3 mm surrounded by erythema was considered positive. In those cases with a history of severe anaphylaxis, we performed the test with increasing dilutions before reaching the maximum concentration.

Specific IgE Determination

Specific IgE was determined using the CAP-PEIA system (Pharmacia Diagnostics) with c6 (amoxicilloyl) following the manufacturer's instructions (21). The results were obtained by
direct comparison with standards run in parallel, considering a value greater than 0.35 kU/L to be positive.

**Synthesis and Characterization of APL**

APL, a molecule with a molecular mass of 3966.6 Da and chemical formula C_{176}H_{250}N_{40}O_{49}S_{8}, was obtained by clogging octa-L-lysine to create a linear chain molecule with 8 recognizable fragments of amoxicilloyl. A schematic representation of the reaction and the resulting structure is shown in Supplementary Figure 1A. Briefly, sodium AX (in excess) and octa-L-lysine were dissolved in aqueous basic pH solution until no traces of octa-L-lysine were detectable. Acidification of the medium to pH <4.5 with HCl solution was followed by precipitation. The product obtained was preparified with resuspension/centrifugation cycles in cold methanol, and the resulting solid mixture was lyophilized. The last purification stage was run through semipreparative chromatography using UV detection, selecting the APL eluting time and discarding the other residues. The resulting product was characterized by proton and carbon nuclear magnetic resonance (1H-NMR and 13C-NMR) performed in a Bruker AV-300 spectrometer, as well as by Fourier transform infrared (FT-IR) spectrometry using a Nicolet Avatar 320 FT-IR spectrometer. The purity of the compound was analyzed using high-performance liquid chromatography (Supplementary Figure 1B).

**Passive Basophil Histamine Release Test**

The PHRT was performed as previously described [22]. Briefly, passive sensitization of basophils was performed using heparinized blood from the same single healthy nonallergic donor, with a confirmed strong reaction to anti-IgE (histamine released, 45 [5] ng/mL) and no response to AX or APL. To remove the IgE bound on the surface of the basophils, 3 mL of blood sample was treated with 10 mL of stripping buffer (0.14 M NaCl, 0.005 M KCl, and 0.0134 M lactic acid) for 10 minutes at 4°C. Then, 0.5 mL of sera from patients or controls was incubated with 3 mL of the “IgE-stripped” donor blood for 60 minutes at 37°C. Aliquots (25 µL) of passively sensitized blood in the presence of IL-3 (2 ng/mL blood) were incubated in the glass fiber–prepared microtiter plates (RefLab ApS) with 25 µL of AX 5 µg/mL or APL 10 µg/mL for 60 minutes at 37°C. The AX and APL concentration chosen for this test was the highest value that did not lead to nonspecific histamine release (>10 ng/mL) in a dose-response curve. This level corresponded to the mean plus 3 standard deviations (SD) of the histamine release values measured in 5 nonallergic persons without a specific stimulus. As a positive control, we used 25 µL of anti-IgE (KPL) at a concentration of 5 µg/mL, as well as histamine at concentrations of 0 and 50 ng/mL.

After incubation, 75 µL of NaOH/ortho-phthalaldehyde (OPA) mixture was added to each well, allowing glass fiber–bound histamine to be released and coupled to OPA. After 10 minutes, the coupling reaction was stopped, and histamine-OPA complexes were stabilized by adding 75 µL of 0.59% HClO₄. Histamine concentrations were determined in a Histareader 501 fluorometer (RefLab) and expressed as ng/mL of histamine released.

**Statistical Analysis**

Quantitative variables were described with the median (IQR). Nonnormally distributed variables were compared using the Mann-Whitney test. Receiver operating characteristic curve analyses were performed to calculate the optimal cut-off value corresponding to the best sensitivity and specificity. All reported P values were 2-tailed, with values <.05 considered statistically significant.

**Results**

APL was synthesized by acylation of the primary amino groups of octa-L-lysine with the β-lactam ring of the AX molecules. The chemical characterization of the resulting conjugate was based on 1H-NMR and 13C-NMR, whose spectra showed the signals corresponding to their structure (Supplementary Figure 1A and B). Characterization was also confirmed by FT-IR spectroscopy, which showed the absorption bands to be consistent with the functional groups included in the structure of the molecule.

The study included 19 patients with immediate hypersensitivity reactions to AX with the presence of serum sIgE to AX. The clinical characteristics and the results of the allergological work-up are shown in the Table. The median (IQR) age was 51 (33-62) years, 6 patients were female, and AX was the drug involved in all reactions. Nine patients developed anaphylaxis, 7 urticaria, and 2 erythema accompanied by intense pruritus; in 1 patient, the clinical reaction, although immediate, was not clearly defined. The median time interval between the reaction and the study was 90 (60-240) days and between drug intake and development of symptoms 24 (10-60) minutes. The median sIgE level to AX was 3.37 (0.95-5.89) kU/L.

The ST results with AX were positive in the immediate reading in 10 patients: 7 had a positive prick test result at the maximum concentration of 20 mg/mL and 3 had a positive intradermal test result also at the maximum concentration of 20 mg/mL. The ST results were negative with AX in 2 patients, although they had a positive intradermal test result with BPOL (patient 10) or with BPOL and MD (patient 11). ST was not performed in 5 patients (4 anaphylaxis and 1 urticaria) owing to patient risk factors (patients 17 and 19) or because of the severity of the reaction (patients 1, 5, and 14). Finally, intradermal testing was not performed in 2 cases with a negative prick test result to AX owing to the high positivity in the CAP assay (6.03 kU/L in patient 8 and 5.26 kU/L in patient 12). No patient developed systemic symptoms after ST, with negative results to BPOL, MD, and AX in all 10 controls.

For standardization of pHRT, we first performed a dose–response study to establish the highest concentration of AX and APL that did not induce nonspecific histamine release corresponding to 3×SD of background values measured in 5 nonallergic participants. We found that 5 µg/mL of either AX or APL were the best concentrations to perform the test and were therefore used for further studies (Supplementary Figure 2).

The pHRT results obtained with AX and APL are shown for each patient in the Table. The results for AX were significantly higher in patients (median, 16.5 [7-22] ng/mL) than in controls.
The results were also higher in patients for APL (median, 19.5 [13-23.5] ng/mL) than in controls (median, 8 [5.13-11] ng/mL). Comparison of the median values of histamine released between patients and controls showed differences using either AX ($P_{.13}$) or APL ($P_{.0013}$), with differences greater for APL (11.5 ng/mL) than for AX (4.5 ng/mL) (Figure 1). Although median histamine release with the APL molecule was higher than that obtained with AX, comparisons were not statistically significant ($P_{.004}$) (Figure 2).

Receiver operating characteristic curve analysis was performed to determine the optimal cut-off value for considering results as positive, with results indicating that values >12.5 ng/mL of histamine were the optimal cut-off for APL and >14.5 ng/mL of histamine for AX (Supplementary Figure 3). Using these cut offs, pHRT with APL revealed 15 out of 19 (79%) positive cases, and pHRT with AX revealed 12 out of 19 (63%) positive cases, thus indicating a higher

### Table 1. Clinical, Demographic Characteristics and Results of Skin Tests and Specific IgE to AX in the Study Population

<table>
<thead>
<tr>
<th>Pat</th>
<th>Age, y</th>
<th>Gender</th>
<th>Reaction</th>
<th>IgE-AXO, kU/L</th>
<th>IntStu, d</th>
<th>IntReac, min</th>
<th>Skin Test-AX, mm</th>
<th>HRT, ng/mL&lt;sup&gt;a&lt;/sup&gt;</th>
<th>AX</th>
<th>APL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>24</td>
<td>Female</td>
<td>Anaphylaxis</td>
<td>1.14</td>
<td>90</td>
<td>5</td>
<td>ND</td>
<td>ND</td>
<td>15&lt;sup&gt;a&lt;/sup&gt;</td>
<td>17.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>2</td>
<td>31</td>
<td>Male</td>
<td>Urticaria</td>
<td>3.37</td>
<td>450</td>
<td>5</td>
<td>Pos (6)</td>
<td>ND</td>
<td>19.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>21.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>57</td>
<td>Male</td>
<td>Anaphylaxis</td>
<td>2.24</td>
<td>60</td>
<td>10</td>
<td>Pos (8)</td>
<td>ND</td>
<td>18&lt;sup&gt;a&lt;/sup&gt;</td>
<td>22&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>4</td>
<td>36</td>
<td>Female</td>
<td>Anaphylaxis</td>
<td>0.95</td>
<td>90</td>
<td>15</td>
<td>ND</td>
<td>Pos (11)</td>
<td>27&lt;sup&gt;a&lt;/sup&gt;</td>
<td>26&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>5</td>
<td>33</td>
<td>Female</td>
<td>Anaphylaxis</td>
<td>1.28</td>
<td>60</td>
<td>18</td>
<td>ND</td>
<td>ND</td>
<td>21&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>6</td>
<td>22</td>
<td>Male</td>
<td>Urticaria</td>
<td>1.65</td>
<td>180</td>
<td>10</td>
<td>Pos (6)</td>
<td>ND</td>
<td>30&lt;sup&gt;a&lt;/sup&gt;</td>
<td>23.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>7</td>
<td>64</td>
<td>Male</td>
<td>Erythema</td>
<td>3.57</td>
<td>90</td>
<td>30</td>
<td>Neg</td>
<td>Pos (10)</td>
<td>27.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>25&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>8</td>
<td>49</td>
<td>Male</td>
<td>Urticaria</td>
<td>6.03</td>
<td>210</td>
<td>60</td>
<td>Neg</td>
<td>ND</td>
<td>27.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>24.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>9</td>
<td>53</td>
<td>Male</td>
<td>Anaphylaxis</td>
<td>5.97</td>
<td>14</td>
<td>90</td>
<td>Pos (5)</td>
<td>ND</td>
<td>22&lt;sup&gt;a&lt;/sup&gt;</td>
<td>17.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>10</td>
<td>66</td>
<td>Male</td>
<td>Urticaria</td>
<td>&gt;100</td>
<td>10</td>
<td>55</td>
<td>Neg</td>
<td>Neg&lt;sup&gt;b&lt;/sup&gt;</td>
<td>21.5</td>
<td>19.5</td>
</tr>
<tr>
<td>11</td>
<td>56</td>
<td>Male</td>
<td>Urticaria</td>
<td>7.03</td>
<td>15</td>
<td>60</td>
<td>Neg</td>
<td>Neg&lt;sup&gt;c&lt;/sup&gt;</td>
<td>12.5</td>
<td>17.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>12</td>
<td>35</td>
<td>Male</td>
<td>Anaphylaxis</td>
<td>5.26</td>
<td>45</td>
<td>30</td>
<td>Neg</td>
<td>ND</td>
<td>17.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>22.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>13</td>
<td>69</td>
<td>Male</td>
<td>NK</td>
<td>3.76</td>
<td>10680</td>
<td>ND</td>
<td>Pos (9)</td>
<td>ND</td>
<td>15&lt;sup&gt;a&lt;/sup&gt;</td>
<td>22&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>14</td>
<td>47</td>
<td>Male</td>
<td>Anaphylaxis</td>
<td>0.85</td>
<td>240</td>
<td>30</td>
<td>ND</td>
<td>ND</td>
<td>8</td>
<td>13&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>15</td>
<td>51</td>
<td>Female</td>
<td>Erythema</td>
<td>5.89</td>
<td>90</td>
<td>60</td>
<td>Pos (8)</td>
<td>ND</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>16</td>
<td>28</td>
<td>Female</td>
<td>Urticaria</td>
<td>0.84</td>
<td>240</td>
<td>60</td>
<td>Pos (6)</td>
<td>ND</td>
<td>4.5</td>
<td>11</td>
</tr>
<tr>
<td>17</td>
<td>57</td>
<td>Male</td>
<td>Urticaria</td>
<td>0.81</td>
<td>180</td>
<td>10</td>
<td>ND</td>
<td>ND</td>
<td>6</td>
<td>5.5</td>
</tr>
<tr>
<td>18</td>
<td>62</td>
<td>Male</td>
<td>Anaphylaxis</td>
<td>0.76</td>
<td>60</td>
<td>5</td>
<td>Pos (7)</td>
<td>ND</td>
<td>5.5</td>
<td>3</td>
</tr>
<tr>
<td>19</td>
<td>74</td>
<td>Female</td>
<td>Anaphylaxis</td>
<td>3.86</td>
<td>240</td>
<td>10</td>
<td>ND</td>
<td>ND</td>
<td>3</td>
<td>24.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Abbreviations: APL: amoxicilloyl-octa-L-lysine; AX: amoxicillin; AXO: amoxicilloyl; HRT: histamine release test; ID: intradermal test; IntReac, time between drug administration and appearance of the symptoms; IntStu, time interval between reaction occurrence and the study; Neg, negative; NK, not known; ND, not done; Pos, positive.

<sup>a</sup>Positive results.

<sup>b</sup>ID positive to BPOL.

<sup>c</sup>ID positive to BPOL and DM.

---

(median, 12 [8.88-12.5] ng/mL). The results were also higher in patients for APL (median, 19.5 [13-23.5] ng/mL) than in controls (median, 8 [5.13-11] ng/mL). Comparison of the median values of histamine released between patients and controls showed differences using either AX ($P_{.13}$) or APL ($P_{.0013}$), with differences greater for APL (11.5 ng/mL) than for AX (4.5 ng/mL) (Figure 1). Although median histamine release with the APL molecule was higher than that obtained with AX, comparisons were not statistically significant (Figure 1). Moreover, a positive correlation was detected between histamine release induced by AX and that induced by APL (Pearson $r=0.631$ and $P_{.004}$) (Figure 2). Receiver operating characteristic curve analysis was performed to determine the optimal cut-off value for considering results as positive, with results indicating that values >12.5 ng/mL of histamine were the optimal cut-off for APL and >14.5 ng/mL of histamine for AX (Supplementary Figure 3). Using these cut offs, pHRT with APL revealed 15 out of 19 (79%) positive cases, and pHRT with AX revealed 12 out of 19 (63%) positive cases, thus indicating a higher
All BLs used in clinical practice can induce allergy, although AX, whether combined or not with clavulanate, is the most common elicitor [1]. AX is a low-molecular-weight molecule formed by a β-lactam ring fused to a thiazolidine ring and a side chain [9]. According to the hapten hypothesis, AX needs to bind covalently to a carrier, usually a protein, in order to produce an immune response; this occurs through the opening of the β-lactam ring by the amino groups of protein lysine residues forming the amoxicilloyl antigenic determinant [25-27]. However, other structures such as amoxicilloylic acid (which results from β-lactam ring hydrolysis) and diketopiperazine (which results from intramolecular acylation by the amino group of the AX side chain) can be formed. These structures have not proven useful in the diagnosis of immediate hypersensitivity reactions using the BAT [16].

The major determinant of BP, BPOL, is a stable product. A prospective multicenter clinical trial showed it to be useful for diagnosing patients with immediate BL allergy using ST [17]. Following the same synthetic approach, we produced APL by acylation of the primary amino groups of octa-L-lysine with the β-lactam ring of AX molecules. We used both APL and AX as reagents in pHRT in order to confirm specific recognition by IgE from allergic patients bound to basophils. We chose pHRT instead of BAT for a number of reasons: (i) It is a simple method that has been improved using glass microfiber plates to which histamine is specifically bound and that enables the tests to be performed in any laboratory independently of the availability of equipment and the need to send them to a reference laboratory; (ii) Up to 10 drugs can be tested on the same plate; (iii) Given the possibility of in vitro determination, the test can be performed only by sending sera to centers where the technology is available. However, it is important to use a single donor with highly responding basophils in order to reduce interindividual variability due to basophil releasability.

Using this method, we obtained a sensitivity of 63% with AX and 79% with APL, and all patients with positive results with AX also had positive results with APL. In addition, specificity was higher with APL (100%) than with AX (80%). We also found a good correlation between positive in vitro histamine release responses to AX and APL, thus indicating that APL is a good reagent for in vitro diagnosis in patients with immediate hypersensitivity reactions to AX, especially if we take into account that we found positive results in 2 cases with negative ST results (Patients 10 and 11) and in 3 cases where ST was not performed (Patients 1, 5, and 19) owing to the severity of the reactions or the high risk for patients. In fact, in the 9 patients with negative ST results to AX, 8 (88.9%) had positive pHRT results with APL and 5 (55.5%) with AX, thus confirming the utility of this test for diagnosis.

Of note, all patients were selected based on a positive CAP result; therefore, pHRT had lower sensitivity for both AX and APL. However, we do not know the sensitivity of either method when compared in a general population with a history of immediate reaction to AX.

In conclusion, we show that pHRT using APL is a promising in vitro method for the evaluation of patients with immediate allergic reactions to AX, including patients in whom ST is negative or cannot be performed. Moreover, it would be

Figure 1. Comparison of results of the basophil passive histamine release (pHRT) test for AX and APL between patients and controls.

Figure 2. Correlation analysis between amoxicillin and APL in the basophil histamine release technique of allergic patients.

sensitivity for APL. The specificity results were also better for APL (100%) than for AX (80%). No patients responded to AX only.

Discussion

Allergy to BLs is a major health problem, and 10% of the population report being allergic, although less than 20% are truly allergic [1,2]. Diagnosis is complex and based mainly on ST, with sensitivity less than 70%, thus implying that DPT is necessary for an accurate diagnosis in a nonnegligible percentage of cases [10-12,14]. The sensitivity of in vitro tests is not optimal and is especially lower with the CAP immunoassay [21,22]. The BAT with the highest sensitivity has the disadvantage that it requires fresh blood. Since pHRT was recently shown to be a useful method for diagnosing patients with immediate allergic reactions to clavulanate with a sensitivity of 55% and specificity of 85%, we applied this methodology in the present study [23].
interesting to analyze the use of APL as a diagnostic reagent in both BAT and ST.

Funding

The present study was supported by the following: Institute of Health “Carlos III” of the Ministry of Economy and Competitiveness (grants cofunded by the European Regional Development Fund (ERDF): P112/02529, P115/01206, CP15/00103, RETICs RIRAAF RD12/0013/0001, RETIC ARADYAL RD16/0006/0001, RD16/0006/0033); Andalusian Regional Ministry of Economy and Knowledge (grants cofunded by European Regional Development Fund [ERDF]: CTS-06603); Andalusian Regional Ministry of Health (grants PI-0699-2011, PI-0159-2013, PI-0179-2014 and PI-0241-2016); Merck-Serono Research Grant from Fundación Salud 2000; and “Premio UNICAJA a la innovación en biomedicina y salud”.

CM holds a “Nicolas Monardes” research contract from the Andalusian Regional Ministry of Health (C-0044-2012 SAS 2013). MIM holds a “Miguel Servet I” grant from the Institute of Health “Carlos III” of the Ministry of Economy and Competitiveness (grant cofunded by the European Social Fund [ESF]: CP15/00103. TDF holds a “Ramón y Cajal” research contract from the Ministry of Economy and Competitiveness (RYC-2013-13138).

Conflicts of Interest

Sidsel Falkencrone and Per Stahl Skov are research consultants for Reflab. Francisca Arribas, David Rodriguez, and Fernando Pineda are employees of DIATER Laboratories.

References


Manuscript received May 18, 2017; accepted for publication June 19, 2017.

Francisca Arribas Poves
DIATER Laboratorios
Avda, Gregorio Peces Barba, 2
Parque Tecnológico de Leganés 28918 Leganés (Madrid), Spain
E-mail: f.arribas@diater.com